Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer | Zendy

Kohei Shitara | Zendy; YungJue Bang | Zendy; Satoru Iwasa | Zendy; Naotoshi Sugimoto | Zendy; MinHee Ryu | Zendy; Daisuke Sakai | Zendy; Hyun Cheol Chung | Zendy; Hisato Kawakami | Zendy; Hiroshi Yabusaki | Zendy; Jeeyun Lee | Zendy; Kaku Saito | Zendy; Yoshinori Kawaguchi | Zendy; Takahiro Kamio | Zendy; Akihito Kojima | Zendy; Masahiro Sugihara | Zendy; Kensei Yamaguchi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

Author(s) -

Kohei Shitara,

YungJue Bang,

Satoru Iwasa,

Naotoshi Sugimoto,

MinHee Ryu,

Daisuke Sakai,

Hyun Cheol Chung,

Hisato Kawakami,

Hiroshi Yabusaki,

Jeeyun Lee,

Kaku Saito,

Yoshinori Kawaguchi,

Takahiro Kamio,

Akihito Kojima,

Masahiro Sugihara,

Kensei Yamaguchi

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2004413

Subject(s) - trastuzumab , medicine , irinotecan , hazard ratio , chemotherapy , oncology , cancer , gastroenterology , paclitaxel , surgery , confidence interval , breast cancer , colorectal cancer

Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. The drug may have efficacy in patients with HER2-positive advanced gastric cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research